Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

Annals of Internal Medicine

Volumn 135, Issue 2, 2001, Pages 73-87

  Jafar, T H ^a   Schmid, C H ^a   Landa, M ^a   Giatras, I ^a   Toto, R ^a   Remuzzi, G ^a   Maschio, G ^a   Brenner, B M ^a   Kamper, A ^a   Zucchelli, P ^a   Becker, G ^a   Himmelmann, A ^a   Bannister, K ^a   Landais, P ^a   Shahinfar, S ^a   De Jong, P E ^a   De Zeeuw, D ^a   Lau, J ^a   Levey, A S ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; PRIORITY JOURNAL; PROTEINURIA; RISK; URINARY EXCRETION;

EID: 0035902622     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-135-2-200107170-00007     Document Type: Article

References (45)

1. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
2. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
3. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy
4. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
5. Renal protective effect of enalapril in diabetic nephropathy
6. Improved kidney function with cilazapril in hypertensive type II diabetics with chronic renal failure
7. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors
8. Nitrendipine and enalapril improve albuminuria and glomerular filtration rate in non-insulin dependent diabetes
9. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial
10. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study
11. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy
12. Long-term comparison between captopril and nifedipine in the progression of renal insufficiency
13. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial
14. Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
15. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure
16. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy
17. ACE inhibition preserves renal function better than beta-blockade in the treatment of essential hypertension
18. Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: A controlled double-blind trial
19. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
20. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
21. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
22. Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: A 1-year follow-up
23. Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy
24. Enalapril versus metoprolol in primary hypertension - Effects on the glomerular filtration rate
25. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease
26. Renal parenchymal hypertension: Current concepts of pathogenesis and management
27. A practical approach to the management of patients with chronic renal failure
28. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: A meta-analysis of randomized trials
29. Antilymphocyte antibodies, renal transplantation, and meta-analysis
30. Estimating survival
31. The Cox proportional hazards model
32. Extending the Cox model
33. Regression diagnostics
34. American Diabetes Association: Clinical practice recommendations 1997
35. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
36. Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease
37. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?
38. Progression of chronic renal disease. Mechanisms, risk factors, and testing of interventions
39. Hemodynamic theory of progressive renal disease: A 10-year update in brief review
40. Renoprotective therapy: Titration against urinary protein excretion
41. Proteins in the urine. 1. Proteinuria mechanisms and characteristic urinary proteins
42. Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: Important differences between practice and published guidelines
43. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients